It is very uncertain whether azelaic acid changes total number of participants who experienced at least one minor… compared with benzoyl peroxide (very low certainty).
Standard‐dose VKA plus single antiplatelet agent showed no clear difference in minor bleedingb compared with standard‐dose VKA (low certainty).
It is very uncertain whether standard‐dose VKA plus single antiplatelet agent changes major bleeding (minor cerebral hemorrhage) compared with single antiplatelet agent (very low certainty).
It is very uncertain whether supine midline head position changes retinopathy of prematurity, > stage 3 compared with any other supine head position (very low certainty).
It is very uncertain whether cervical cerclage in combination with antibiotics and tocolytics changes serious neonatal morbidity (Reported in Miller 2014 as 'composite… compared with cervical cerclage alone (very low certainty).
It is very uncertain whether topical antibiotics changes resolution of ear discharge (1 to 2 weeks) Aminoglycosides compared with acetic acid (very low certainty).
Citicoline showed no clear difference in neurological functionPatients with minor impairment (according to ≤… compared with placebo or standard treatment (low certainty).
The review found no eligible studies for this question.
Mepolizumab 100 mg leads to lower rate of moderate or severe exacerbations Eosinophilic phenotype compared with placebo (high certainty).
Mepolizumab 300 mg showed no clear difference in rate of moderate or severe exacerbations Eosinophilic phenotype compared with placebo (moderate certainty).
Mepolizumab 300 mg probably leads to lower time to first moderate or severe exacerbation Eosinophilic phenotype compared with placebo (moderate certainty).
Mepolizumab 300 mg showed no clear difference in rate of exacerbations with ED visit or hospitalisations Eosinophilic… compared with placebo (moderate certainty).
Benralizumab 10 mg showed no clear difference in rate of moderate or severe exacerbations Eosinophils ≥ 220/μL compared with placebo (moderate certainty).
Benralizumab 10 mg showed no clear difference in rate of moderate or severe exacerbations Eosinophils < 220/μL compared with placebo (moderate certainty).
Benralizumab 10 mg probably leads to lower rate of severe exacerbations requiring hospitalisation Eosinophils ≥… compared with placebo (moderate certainty).
Benralizumab 30 mg showed no clear difference in rate of moderate or severe exacerbations Eosinophils ≥ 220/μL compared with placebo (moderate certainty).
Benralizumab 30 mg showed no clear difference in rate of moderate or severe exacerbations Eosinophils < 220/μL compared with placebo (moderate certainty).